Literature DB >> 23940430

Correlation between CHADS2 score and anticoagulant use in atrial fibrillation: Results of a mini-survey.

Gerry Cartman1, Mark Blostein, Mark J Eisenberg.   

Abstract

Quality assurance in atrial fibrillation is related to the appropriate use of anticoagulation. The CHADS2 score is widely used to determine which patients should or should not be anticoagulated. The authors hypothesized that as thromboembolic risk and, therefore, the CHADS2 score increases, so should the rate of anticoagulant prescription. The authors found a positive correlation between CHADS2 score and anticoagulant prescription (r=0.8) in a mini-survey. Although anticoagulant use at CHADS2 score = 0 was presumed to be very low, it was found to be higher than expected. This was readily explained by a group of low-risk patients being anticoagulated before cardioversion. Cardioverted patients were then examined as a group and it was found that the rate of rhythm control decreased with CHADS2 score (r= -0.89), a finding that has not been reported in the literature and may warrant further investigation.

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Cardioversion, CHADS2 score; Quality assurance in cardiology

Year:  2013        PMID: 23940430      PMCID: PMC3718585     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  9 in total

1.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

Review 3.  Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation.

Authors:  Matthew D Solomon; Aditya J Ullal; Donald D Hoang; James V Freeman; Paul Heidenreich; Mintu P Turakhia
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2012-02       Impact factor: 2.160

4.  Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapy.

Authors:  Sara L Partington; Simona Abid; Koon Teo; Wesley Oczkowski; Martin J O'Donnell
Journal:  Thromb Res       Date:  2007-04-16       Impact factor: 3.944

5.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

Authors:  John A Cairns; Stuart Connolly; Sean McMurtry; Michael Stephenson; Mario Talajic
Journal:  Can J Cardiol       Date:  2011 Jan-Feb       Impact factor: 5.223

6.  Rhythm control versus rate control for atrial fibrillation and heart failure.

Authors:  Denis Roy; Mario Talajic; Stanley Nattel; D George Wyse; Paul Dorian; Kerry L Lee; Martial G Bourassa; J Malcolm O Arnold; Alfred E Buxton; A John Camm; Stuart J Connolly; Marc Dubuc; Anique Ducharme; Peter G Guerra; Stefan H Hohnloser; Jean Lambert; Jean-Yves Le Heuzey; Gilles O'Hara; Ole Dyg Pedersen; Jean-Lucien Rouleau; Bramah N Singh; Lynne Warner Stevenson; William G Stevenson; Bernard Thibault; Albert L Waldo
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

7.  Current status of anticoagulation therapy for elderly atrial fibrillation patients in Japan: from Hokuriku atrial fibrillation trial.

Authors:  Hiroshi Furusho; Masayuki Takamura; Shigeo Takata; Satoru Sakagami; Motoaki Hirazawa; Takeshi Kato; Hisayoshi Murai; Masaki Okajima; Shuichi Kaneko
Journal:  Circ J       Date:  2008-10-14       Impact factor: 2.993

8.  ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society.

Authors:  N A Mark Estes; Jonathan L Halperin; Hugh Calkins; Michael D Ezekowitz; Paul Gitman; Alan S Go; Robert L McNamara; Joseph V Messer; James L Ritchie; Sam J W Romeo; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2008-02-18       Impact factor: 29.690

9.  A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice.

Authors:  T P Van Staa; E Setakis; G L Di Tanna; D A Lane; G Y H Lip
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

  9 in total
  1 in total

1.  Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study.

Authors:  Siti Norain Azahar; Saperi Sulong; Wan Asyraf Wan Zaidi; Norliza Muhammad; Yusof Kamisah; Norliana Masbah
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.